Mark Smith, Finch CEO

FDA lifts hold on Finch’s mi­cro­bio­me crap­sule, as com­pa­ny looks to right ship

Finch Ther­a­peu­tics’ lead pro­gram may fly again.

The mi­cro­bio­me com­pa­ny an­nounced Thurs­day that the FDA lift­ed a two-month hold on clin­i­cal tri­als for its ex­per­i­men­tal treat­ment for re­cur­rent C. diff, a po­ten­tial­ly fa­tal bac­te­r­i­al in­fec­tion. Al­though the com­pa­ny still has to take sev­er­al steps be­fore it can re­sume its piv­otal study, the lift re­moves an un­usu­al pan­dem­ic-re­lat­ed hur­dle for Finch as the biotech looks to get its first ther­a­py over the fin­ish line and sta­bi­lize a pre­car­i­ous fi­nan­cial sit­u­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.